NANOSONICS LIMITED (NAN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NAN

NAN - NANOSONICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.31
Index: ASX200 | ASX300 | ALL-ORDS

Nanosonics is an Australian medical device company manufacturing high level disinfection systems to reduce the spread of infection. Founded in 2001, the company listed on the ASX in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.05

15 Sep
2025

0.160

OPEN

$3.89

4.11%

HIGH

$4.06

947,286

LOW

$3.83

TARGET
$4.55 12.3% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
NAN: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 6.8 7.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx 59.3% 5.6% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 56.4 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx6.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx198.3 M
Book Value Per Share xxxxxxxxxxxxxxx69.1
Net Operating Cash Flow xxxxxxxxxxxxxxx44.0 M
Net Profit Margin xxxxxxxxxxxxxxx10.43 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx10.55 %
Return on Invested Capital xxxxxxxxxxxxxxx10.27 %
Return on Assets xxxxxxxxxxxxxxx7.99 %
Return on Equity xxxxxxxxxxxxxxx10.55 %
Return on Total Capital xxxxxxxxxxxxxxx8.01 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx35.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx4 M
Total Debt xxxxxxxxxxxxxxx8 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx162 M
Price To Book Value xxxxxxxxxxxxxxx5.86

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx8.7 M
Capex % of Sales xxxxxxxxxxxxxxx4.40 %
Cost of Goods Sold xxxxxxxxxxxxxxx50 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx131 M
Research & Development xxxxxxxxxxxxxxx32 M
Investments - Total xxxxxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.1

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

21/03/2025

2

Accumulate

$4.55

12.35%

The FDA has approved Nanosonics' Coris device, which is designed to automate the cleaning and reprocessing of flexible endoscopes, under what is referred to as De Novo clearance, Ord Minnett observes.

The analyst believes the approval will boost investor confidence and sentiment, with the launch scheduled for 1Q 2026 in Europe and North America in 2H 2026.

The target price is set at $4.55 with an Accumulate rating.

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

01/09/2025

1

Buy

$5.43

34.07%

Nanosonics' FY25 revenue was up 17% y/y to $198.6m, beating Canaccord Genuity's forecast and the consensus. EBITDA was up 54% y/y and still ahead of the broker's and consensus forecasts.

The broker notes service/consumables revenue rose 20% y/y, reinforcing confidence in growing annuity revenue per installed Trophon unit. The FY26 revenue guidance is for 10% growth at midpoint, and was 3% ahead of the consensus. 

Gross margins are expected to be hit by tariffs, but operating costs remain tightly managed. Coris launch strategy is largely unchanged, with gradual rollout in Europe/Australia but US launch now pushed back to FY27.

The broker lifted FY26 revenue forecast by 2.8% and FY27 by 1.6%. But EBITDA forecasts for FY26-27 are lowered by around -4.5%.

Buy. Target lifted to $5.43 from $5.15.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 6.84 cents.
Canaccord Genuity forecasts a full year FY27 EPS of 11.36 cents.
Access Extra Coverage Research History >

NAN STOCK CHART

FNArena News on NAN

1
Australian Broker Call *Extra* Edition – Sep 03, 2025

Sep 03 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Sep 01, 2025

Sep 01 2025 - Daily Market Reports
3
FNArena Corporate Results Monitor – 27-08-2025

Aug 27 2025 - Australia
4
Australian Broker Call *Extra* Edition – Aug 18, 2025

Aug 18 2025 - Daily Market Reports
5
Rudi’s View: BlueScope Steel, IGO, GrainCorp, Pilbara Minerals, Santos & More

Aug 14 2025 - Rudi's View

Latest Medical Equipment & Devices News

1
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
2
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
3
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
4
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
5
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
6
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
7
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
8
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
9
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
10
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia